ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

tucidinostat

Also written as “Chidamide”, “Tucidinostat” and “HBI-8000”.

Its studies are mostly in Lymphoma, T-Cell, Peripheral · Carcinoma, Non-Small-Cell Lung · Melanoma · Breast Neoplasms · Lymphoma, Non-Hodgkin, led by 4 companies.

Drug pageTucidinostat: every studyAll 185 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jun 17, 201519 company-led studies, 5 open or runningNext primary completion: Jun 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Chipscreen Biosciencesits history only92 open or runningphase 3since Jun 17, 2015Apr 12, 2013May 31, 2028phase 3 · NCT06497985
HUYABIO International, LLC.71 open or runningphase 3since Dec 7, 2020Oct 5, 2015none ahead
Great Novel Therapeutics Biotech & Medicalsits history only21 open or runningphase 2since Feb 7, 2023Feb 7, 2023Jun 2027phase 2 · NCT05833724
Jiangsu HengRui Medicineits history only11 open or runningphase 3since Nov 5, 2023Nov 5, 2023none ahead

Also a collaborator on its studies: Bristol-Myers Squibb and Iqvia Pty.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of HUYABIO International, LLC. only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Oct 5, 2015First study: phase 1 study in Breast NeoplasmsFirst studyNCT02569489
  2. Feb 17, 2016Phase 1 study in Lymphoma, Non-HodgkinNCT02697552 · 13 enrolled · Japan
  3. Mar 15, 2016Phase 2 study in MelanomaNCT02718066 · 96 enrolled · United States
  4. Jun 9, 2016Named tucidinostatINNProposed as its International Nonproprietary Name in WHO's List 115 · before, HBI-8000
  5. Nov 1, 20162 phase 2 studiesNCT02955589, NCT02953652
  6. Dec 7, 2020Phase 3 study in MelanomaNCT04674683 · 450 enrolled · United States, Australia, Austria and more
  7. Nov 19, 2021Phase 2 study in Carcinoma, Non-Small-Cell LungNCT05141357 · 5 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 7 HUYABIO International, LLC. leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05141357Carcinoma, Non-Small-Cell Lung · United States2TerminatedApr 19, 20235
NCT04674683Melanoma · United States, Australia, Austria and more3Active, not recruitingJul 2026450
NCT02955589Precursor T-Cell Lymphoblastic Leukemia-Lymphoma · Japan2CompletedDec 201823
NCT02953652Lymphoma, T-Cell, Peripheral · Japan, Korea, Republic of2CompletedFeb 17, 202255
NCT02718066Melanoma · United States2CompletedDec 12, 202396
NCT02697552Lymphoma, Non-Hodgkin · Japan1CompletedOct 201613
NCT02569489Breast Neoplasms1WithdrawnDec 20150

How it is read

Names in the registry

  • “Chidamide”, 7 entries
  • “Tucidinostat”, 4 entries
  • “HBI-8000”, 4 entries
  • “HBI-8000 in combination with nivolumab”, 2 entries
  • “SHR2554 analog tablets; Chidamide”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.